Gosset Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Atopia Therapeutics General Information
Preclinical studies of ATP-R13 have shown promising results in murine models of allergic asthma, demonstrating improved airway responsiveness, reduced airway remodeling, and decreased inflammation. The therapy induces immune tolerance by promoting regulatory T cell development and aims to address the root cause of allergic diseases rather than just symptoms. Clinical development preparations are ongoing.[3][7]
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Geneva, Geneva Canton
Switzerland
Switzerland
Drug Pipeline
AT-001
Pre-clinicalKey Partnerships
None publicly disclosed as of May 2024.
Atopia Therapeutics Funding
No funding data available
To view Atopia Therapeutics's complete valuation and funding history, request access »